Advertisement

Advertisement

Genomics/Genetics

Nobel Laureate David Baltimore, PhD, Plays Integral Role in Linking Cell Biology and Cancer Genetics

David Baltimore, PhD, whose work profoundly influenced international science, was born on March 7, 1938, in Queens, New York, to Gertrude and Richard Baltimore. While he was in second grade, the family moved to Great Neck, New York, a middle-class suburb with top-notch public schools. “My father...

CNS Cancers
Genomics/Genetics

Key Gene Controlling Tumor Growth in Gliomas Pinpointed

Cedars-Sinai investigators have identified a stem cell–regulating gene that affects tumor growth in patients with brain cancer and may strongly influence survival rates of patients. The findings, published by Edwards et al in Scientific Reports,1 may move physicians closer to their goal of better...

Breast Cancer
Genomics/Genetics

Germline Genetic Testing and Treatment Decisions in Early-Stage Breast Cancer

As reported in the Journal of Clinical Oncology by Allison W. Kurian, MD, of Stanford University School of Medicine, and colleagues, surveys in a population-based sample of patients recently diagnosed with breast cancer indicate that many undergo genetic risk testing without seeing a genetics...

Breast Cancer
Genomics/Genetics

Provision of Genetic Services to Women With Breast Cancer: We Must Do Much Better

Genetic testing for inherited cancer susceptibility is increasingly part of the care of cancer patients and their relatives. Early clinical guidelines recommended BRCA1/2 testing for women diagnosed with breast or ovarian cancer if they also have a significant family cancer history or Ashkenazi...

Hematologic Malignancies
Breast Cancer
Lung Cancer
Kidney Cancer
Sarcoma
Bladder Cancer
Colorectal Cancer
Multiple Myeloma
Genomics/Genetics

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering 8 tumor types. Guidelines are now published for more than 60 tumor types and...

Breast Cancer
Genomics/Genetics

Suboptimal Genetic Testing and Counseling Among Women With Newly Diagnosed Breast Cancer

In a population-based study reported in a research letter in JAMA, Allison W. Kurian, MD, of Stanford University School of Medicine, and colleagues found that genetic testing and genetic counseling are suboptimal among women with newly diagnosed breast cancer.1 Study Details The study involved...

Genomics/Genetics

Recognizing Major Role of Random Mutations in Causing Cancer Does Not Diminish Importance of Primary Prevention

Random mistakes made during DNA replication are responsible for about two-thirds of the mutations that cause human cancers, according to a study reported in Science.1 Recognizing the role of these replication errors “does not diminish the importance of primary prevention but emphasizes that not all ...

Genomics/Genetics

‘It Is What It Is’

Mark looked at me shyly through his oversized Elvis Costello–style glasses. Was he feeling embarrassed by his own reply or just waiting for my reaction? He was sitting between his mom and dad, wearing a t-shirt with a huge Minion print. His braces showed when he smiled, something he does often in...

genomics/genetics

Angela R. Bradbury, MD, on Genetic Information and Clinical Care

Angela R. Bradbury, MD, of the University of Pennsylvania, discusses genetic testing, tumor profiling, and the identification of those at increased risk for second cancers.

Genomics/Genetics

ASCO, AMP, and CAP Issue New Joint Guidelines to Standardize Interpretation and Reporting of Sequence Variants in Cancer

On December 16, a set of joint guidelines developed by ASCO, the Association for Molecular Pathology (AMP), and the College of American Pathologists (CAP) on standardizing the interpretation and reporting of sequence variants in cancer was published online, ahead of the January print issue of The...

Genomics/Genetics

Understanding Cancer Epigenetics and Its Clinical Implications

The field of epigenetics emerged in the 1990s and has been described with somewhat variable meanings. In 2008, a meeting at the Cold Spring Harbor laboratory arrived at a definition of epigenetics by consensus: “A stably heritable phenotype resulting from changes in a chromosome without...

Breast Cancer
Genomics/Genetics

Use of Genetic Testing to Identify Patients With Breast Cancer at High Risk for Venous Thromboembolism

Venous thromboembolism is a serious—and sometimes fatal—complication of cancer and chemotherapy treatment. Since breast cancer is one of the most common cancers, it accounts for a large number of cancer-related cases of venous thromboembolism. Routine thromboprophylaxis, however, is not recommended ...

Breast Cancer
Genomics/Genetics

Expert Point of View: Leif Ellisen, MD, PhD

Results of this trial have been anticipated for a long time. Women were enrolled between 2000 and 2008,” said Leif Ellisen, MD, PhD, Program Director of Breast Medical Oncology at Massachusetts General Hospital Cancer Center in Boston. Regarding the survival advantage in triple-negative...

Breast Cancer
Genomics/Genetics

BRCA Status Does Not Seem to Affect Survival Outcomes in Young Women With Early Breast Cancer

Young women who carry the BRCA1 and/or BRCA2 mutation and develop breast cancer seem to have similar survival compared with young women who have BRCA-negative breast cancer. However, women with BRCA-positive triple-negative breast cancer have an 11% survival advantage compared with those with...

Breast Cancer
Genomics/Genetics

Genomic Landscape of Metastatic Breast Cancer Differs From That of Primary Breast Cancer

Researchers working on whole-exome and transciptome sequencing of endocrine-resistant estrogen receptor–positive metastatic breast cancer have shown that the mutational landscape differs from that of estrogen receptor–positive primary breast cancer, and these differences have the potential to...

Genomics/Genetics
Bladder Cancer

Mutational Characteristics of Chemotherapy-Treated Bladder Urothelial Neoplasms

Radical cystectomy with urinary diversion is the standard of care for muscle invasive bladder cancer.1 Meta-analyses of prospective data have shown a 5% overall survival benefit at 5 years for those receiving neoadjuvant systemic chemotherapy prior to cystectomy.2,3 We currently know of two...

Genomics/Genetics
Bladder Cancer

Study Identifies Factors in Clonal Evolution of Chemotherapy-Resistant Urothelial Carcinoma

In a study reported in Nature Genetics, Bishoy M. Faltas, MD, of Weill Cornell Medicine, and colleagues identified factors in the clonal evolution of chemotherapy-resistant urothelial carcinoma.1 As stated by the investigators: “Chemotherapy-resistant urothelial carcinoma has no uniformly curative...

breast cancer
genomics/genetics

Nikhil Wagle, MD, on Breast Cancer: Advances in Genomics

Nikhil Wagle, MD, Dana-Farber Cancer Institute, discusses the genomic sequencing of ER-positive metastatic breast cancer that has become resistant to therapies and the implications for the choice of next therapy, clinical trial eligibility, and novel drug targets (Abstract S1-01).

breast cancer
genomics/genetics

Jennifer A. Ligibel, MD, on Gene Expression: Study Findings

Jennifer A. Ligibel, MD, of Harvard Medical School, discusses the impact of preoperative exercise on breast cancer gene expression (Abstract S5-05).

Breast Cancer
Genomics/Genetics

Chemotherapy May Be Avoidable in Some Women With Early-Stage Breast Cancer Based on Clinical and Genomic Risks

In the phase III MINDACT trial reported in The New England Journal of Medicine, Fatima Cardoso, MD, of Champalimaud Clinical Center–Champalimaud Foundation, Lisbon, and colleagues found that adjuvant chemotherapy may be avoidable in women with early-stage breast cancer who are at high clinical...

Genomics/Genetics

Using Pharmacogenetics to Predict Cancer Prognosis, Response to Treatment, and Toxicity

Although clinical trials are helpful in determining the effectiveness of a specific drug across a patient population, they are not as reliable at pinpointing how well a particular patient will respond to the drug or dosing regimen or how the drug may impact the patient’s quality of life from...

genomics/genetics
solid tumors

Janessa J. Laskin, MD, on Tumor Gene Expression and Advanced Cancers

Janessa J. Laskin, MD, of the British Columbia Cancer Agency, discusses the ways in which availability of tumor gene expression data facilitates clinical decision-making for patients with advanced cancers. (Abstract 1519O)

Genomics/Genetics

Using Watson to Analyze Genomic Data to Personalize Treatment for Patients With Cancer

Three years ago, IBM’s Watson supercomputer was best known for defeating two former champions on the TV game show Jeopardy! Today, it is grabbing headlines for becoming an important assistant in cancer care. Able to read and understand millions of pages of text within seconds, Watson caught the...

Issues in Oncology
Genomics/Genetics

Psychological Impact of Genetic Testing to Be Explored in Subset of NCI-MATCH Trial Patients

The Eastern Cooperative Oncology Group–American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group has received federal approval to add a quality-of-life research study, Communication and Education in Tumor Profiling (EAQ152), or COMET, to the NCI-MATCH (EAY131) trial, which is ...

Breast Cancer
Issues in Oncology
Genomics/Genetics

Using Social Media to Accelerate Genomic Research

The success of using social media to push forward causes for social good was a driving factor in the launch this past October of the Metastatic Breast Cancer Project (MBC project), which aims to accelerate the understanding of what makes patients with metastatic breast cancer genetically unique....

Advertisement

Advertisement

Advertisement